Latest & greatest articles for tuberculosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on tuberculosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on tuberculosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for tuberculosis

161. β-Lactams against Tuberculosis - New Trick for an Old Dog? Full Text available with Trip Pro

β-Lactams against Tuberculosis - New Trick for an Old Dog? 27433841 2016 08 05 2016 07 28 1533-4406 375 4 2016 Jul 28 The New England journal of medicine N. Engl. J. Med. β-Lactams against Tuberculosis--New Trick for an Old Dog? 393-4 10.1056/NEJMc1513236 Diacon Andreas H AH Stellenbosch University, Cape Town, South Africa ahd@sun.ac.za. van der Merwe Lize L Task Applied Science, Cape Town, South Africa. Barnard Marinus M Task Applied Science, Cape Town, South Africa. von Groote-Bidlingmaier (...) Agents 0 beta-Lactamase Inhibitors 0 beta-Lactams 74469-00-4 Amoxicillin-Potassium Clavulanate Combination AIM IM Amoxicillin-Potassium Clavulanate Combination therapeutic use Antitubercular Agents therapeutic use Colony Count, Microbial Drug Discovery Humans Mycobacterium tuberculosis Tuberculosis, Multidrug-Resistant drug therapy beta-Lactamase Inhibitors therapeutic use beta-Lactams therapeutic use 2016 7 20 6 0 2016 7 20 6 0 2016 8 6 6 0 ppublish 27433841 10.1056/NEJMc1513236

2016 NEJM

162. Tuberculosis and AIDS: major progress

Tuberculosis and AIDS: major progress Prescrire IN ENGLISH - Spotlight ''Tuberculosis and AIDS: major progress'', 1 July 2016 {1} {1} {1} | | > > > Tuberculosis and AIDS: major progress Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Tuberculosis and AIDS: major progress AIDS and tuberculosis still rank among the leading causes of death worldwide

2016 Prescrire

163. Baeyer-Villager monooxygenases EthA and MymA are required for activation of inhibitors against replicating and non-replicating Mycobacterium tuberculosis Full Text available with Trip Pro

Baeyer-Villager monooxygenases EthA and MymA are required for activation of inhibitors against replicating and non-replicating Mycobacterium tuberculosis Successful treatment of Mycobacterium tuberculosis infection typically requires a complex regimen administered over at least 6 months. Interestingly, many of the antibiotics used to treat M. tuberculosis are prodrugs that require intracellular activation. Here, we describe three small molecules, active against both replicating and non (...) -replicating M. tuberculosis, that require activation by Baeyer-Villiger monooxygenases (BVMOs). Two molecules require BVMO EthA (Rv3854c) for activation and the third molecule requires the BVMO MymA (Rv3083). While EthA is known to activate the antitubercular drug ethionamide, this is the first description of MymA as an activating enzyme of a prodrug. Furthermore, we found that MymA also plays a role in activating ethionamide, with loss of MymA function resulting in ethionamide-resistant M. tuberculosis

2016 Cell chemical biology

164. Misdiagnosis of Cancer as Tuberculosis in Low- to Middle-Income Countries: A Tip of the Iceberg! Full Text available with Trip Pro

Misdiagnosis of Cancer as Tuberculosis in Low- to Middle-Income Countries: A Tip of the Iceberg! 28717707 2019 01 13 2378-9506 2 4 2016 Aug Journal of global oncology J Glob Oncol Misdiagnosis of Cancer as Tuberculosis in Low- to Middle-Income Countries: A Tip of the Iceberg! 244-245 10.1200/JGO.2016.004457 Hannan Abdul A East Tennessee State University, Johnson City, TN. eng Journal Article 2016 05 18 United States J Glob Oncol 101674751 2378-9506 The following represents disclosure

2016 Journal of global oncology

165. OsdR of Streptomyces coelicolor and the Dormancy Regulator DevR of Mycobacterium tuberculosis Control Overlapping Regulons Full Text available with Trip Pro

OsdR of Streptomyces coelicolor and the Dormancy Regulator DevR of Mycobacterium tuberculosis Control Overlapping Regulons Two-component regulatory systems allow bacteria to respond adequately to changes in their environment. In response to a given stimulus, a sensory kinase activates its cognate response regulator via reversible phosphorylation. The response regulator DevR activates a state of dormancy under hypoxia in Mycobacterium tuberculosis, allowing this pathogen to escape the host (...) defense system. Here, we show that OsdR (SCO0204) of the soil bacterium Streptomyces coelicolor is a functional orthologue of DevR. OsdR, when activated by the sensory kinase OsdK (SCO0203), binds upstream of the DevR-controlled dormancy genes devR, hspX, and Rv3134c of M. tuberculosis. In silico analysis of the S. coelicolor genome combined with in vitro DNA binding studies identified many binding sites in the genomic region around osdR itself and upstream of stress-related genes. This binding

2016 mSystems

166. Immune reconstitution inflammatory syndrome in a HIV-infected patient with disseminated tuberculosis Full Text available with Trip Pro

Immune reconstitution inflammatory syndrome in a HIV-infected patient with disseminated tuberculosis Immune reconstitution inflammatory syndrome (IRIS) is the paradoxical worsening of pre-existing infectious processes after commencement of anti-retroviral therapy (ART) in HIV-infected patients. Its manifestations are dependent on the underlying opportunistic infections. We report a case of an HIV-infected patient with disseminated tuberculosis, who responded to anti-tuberculosis therapy

2016 Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia

167. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Full Text available with Trip Pro

A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Identification of blood biomarkers that prospectively predict progression of Mycobacterium tuberculosis infection to tuberculosis disease might lead to interventions that combat the tuberculosis epidemic. We aimed to assess whether global gene expression measured in whole blood of healthy people allowed identification of prospective signatures of risk of active tuberculosis disease.In this prospective cohort study (...) , we followed up healthy, South African adolescents aged 12-18 years from the adolescent cohort study (ACS) who were infected with M tuberculosis for 2 years. We collected blood samples from study participants every 6 months and monitored the adolescents for progression to tuberculosis disease. A prospective signature of risk was derived from whole blood RNA sequencing data by comparing participants who developed active tuberculosis disease (progressors) with those who remained healthy (matched

2016 Lancet

168. Design and construction of a DNA origami drug delivery system based on MPT64 antibody aptamer for tuberculosis treatment Full Text available with Trip Pro

Design and construction of a DNA origami drug delivery system based on MPT64 antibody aptamer for tuberculosis treatment With all of the developments on infectious diseases, tuberculosis (TB) remains a cause of death among people. One of the most promising assembly techniques in nano-technology is "scaffolded DNA origami" to design and construct a nano-scale drug delivery system. Because of the global health problems of tuberculosis, the development of potent new anti-tuberculosis drug delivery (...) system without cross-resistance with known anti-mycobacterial agents is urgently needed. The aim of this study was to design a nano-scale drug delivery system for TB treatment using the DNA origami method.In this study, we presented an experimental research on a DNA drug delivery system for treating Tuberculosis. TEM images were visualized with an FEI Tecnai T12 BioTWIN at 120 kV. The model was designed by caDNAno software and computational prediction of the 3D solution shape and its flexibility

2016 Electronic physician

169. Systematic Survey of Serine Hydrolase Activity in Mycobacterium tuberculosis Defines Changes Associated with Persistence Full Text available with Trip Pro

Systematic Survey of Serine Hydrolase Activity in Mycobacterium tuberculosis Defines Changes Associated with Persistence The transition from replication to non-replication underlies much of Mycobacterium tuberculosis (Mtb) pathogenesis, as non- or slowly replicating Mtb are responsible for persistence and poor treatment outcomes. Therapeutic targeting of non-replicating populations is a priority for tuberculosis treatment, but few drug targets in non-replicating Mtb are currently known. Here

2016 Cell chemical biology

170. Tuberculosis

Tuberculosis T T uberculosis uberculosis NICE guideline Published: 13 January 2016 nice.org.uk/guidance/ng33 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take (...) an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Tuberculosis (NG33) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 178Contents Contents Overview 4 Who is it for? 4 Recommendations 5 1.1 Preventing TB 5 1.2 Latent TB 15 1.3 Active TB 24 1.4 Drug resistant TB 40 1.5 Infection control 42 1.6 Case finding 47 1.7

2016 National Institute for Health and Clinical Excellence - Clinical Guidelines

171. Clinical analysis of retroperitoneoscopic nephroureterectomy for renal tuberculosis Full Text available with Trip Pro

Clinical analysis of retroperitoneoscopic nephroureterectomy for renal tuberculosis To explore the feasibility and safety of retroperitoneoscopic nephroureterectomy for kidney tuberculosis.Forty-eight retroperitoneoscopic nephroureterectomies and thirty-five nephroureterectomies for kidney tuberculosis procedures were performed from June 2008 to December 2014. The patients consisted of 53 males and 30 females with a mean age of 36 years (range: 26-51 years). The patients' data were reviewed (...) , and infection at the incision site was observed in two patients, there were no obvious difference between the two surgical methods (P > 0.05). Seventy-five patients were followed up, and the average follow-up time was 12.5 months (range: 6-20 months). All the patients recovered without any lesions remaining.The results of this study indicate that retroperitoneoscopic nephroureterectomy is a feasible, safe, effective, and less invasive treatment modality for treating renal tuberculosis.

2016 Chronic diseases and translational medicine

172. Smoking cessation interventions for pulmonary tuberculosis treatment outcomes. (Abstract)

Smoking cessation interventions for pulmonary tuberculosis treatment outcomes. Active smoking increases the risk of tuberculosis (TB) infection 2 to 2.5 times and is significantly associated with recurrent TB and TB mortality. Observational studies have shown associations between smoking and poor TB treatment outcomes such as increased loss to follow-up rate, severity of disease, drug resistance and slow smear conversion. Since most smoking-related immunologic abnormalities are reversible

2016 Cochrane

173. Tuberculosis Diagnosis Delaying Treatment of Cancer: Experience From a New Oncology Unit in Blantyre, Malawi Full Text available with Trip Pro

Tuberculosis Diagnosis Delaying Treatment of Cancer: Experience From a New Oncology Unit in Blantyre, Malawi Malawi is a low-income country in sub-Saharan Africa with limited health care infrastructure and high prevalance of HIV and tuberculosis. This study aims to determine the characteristics of patients presenting to Queen Elizabeth Central Hospital Oncology Unit, Blantyre, Malawi, who had been treated for tuberculosis before they were diagnosed with cancer.Clinical data on all patients (...) presenting to the oncology unit at Queen Elizabeth Central Hospital from 2010 to 2014 after a prior diagnosis of tuberculosis were prospectively recorded, and a descriptive analysis was undertaken.Thirty-four patients who had been treated for tuberculosis before being diagnosed with cancer were identified between 2010 and 2014, which represents approximately 1% of new referrals to the oncology unit. Forty-one percent of patients were HIV positive. Mean duration of tuberculosis treatment before

2016 Journal of global oncology

174. Collision of Three Pandemics: The Coexistence of Cervical Cancer, HIV Infection, and Prior Tuberculosis in the Sub-Saharan Country of Botswana Full Text available with Trip Pro

Collision of Three Pandemics: The Coexistence of Cervical Cancer, HIV Infection, and Prior Tuberculosis in the Sub-Saharan Country of Botswana Cervical cancer is the leading cause of cancer-related mortality in the developing world, where HIV and Mycobacterium tuberculosis (TB) infection are also endemic. HIV infection is independently associated with increased morbidity and mortality among women with cervical cancer. TB is believed to increase the risk of malignancies and could cause chronic

2016 Journal of global oncology

175. Clinical Practice Guidelines on Prevention, Diagnosis and Management of Tuberculosis

Clinical Practice Guidelines on Prevention, Diagnosis and Management of Tuberculosis Academy of Medicine Singapore College of Family Physicians, Singapore Singapore Medical Association Chapter of Infectious Disease Physicians College of Physicians, Singapore Chapter of Respiratory Physicians College of Physicians, Singapore MOH Clinical Practice Guidelines 1/2016 Mar 2016 MINISTRY OF HEALTH SINGAPORE Prevention, Diagnosis and Management of Tuberculosis ISBN 978-981-09-8528-8 Ministry of Health (...) development group. Inside Back CoverA Prevention, Diagnosis and Management of Tuberculosis CLINICAL PRACTICE GUIDELINES MOH Clinical Practice Guidelines 1/2016 B Published by Ministry of Health, Singapore 16 College Road, College of Medicine Building Singapore 169854 Printed by Kwok Printers Pte Ltd Copyright © 2016 by Ministry of Health, Singapore ISBN 978-981-09-8528-8 Available on the MOH website: http://www.moh.gov.sg/cpg These guidelines are not intended to serve as a standard of medical care

2016 Ministry of Health, Singapore

176. BTS Clinical Statement on the Management of Multidrug-Resistant Tuberculosis (MDRTB)

BTS Clinical Statement on the Management of Multidrug-Resistant Tuberculosis (MDRTB) CLINICAL ST A TEMENT November 2016 THE MANAGEMENT OF MUL TIDRUG-RESIST ANT TUBERCULOSIS (MDRTB) CONTEXT The World Health Organization (WHO) has recently updated its guidance on the management of MDRTB (June 2016). Worldwide, there were an estimated 480,000 cases of MDRTB in 2014, the highest rates being in those from Eastern Europe and the Central Asian republics. In the same year , there were 52 notified cases (...) in England (1.4% of all TB); treatment was completed within 24 months in just 54% cases. The management of MDRTB is more complex and associated with more adverse effects than standard treatment. Prior to effective chemotherapy, about a third of patients with tuberculosis remained alive but with a persistently positive sputum smear , i.e. they remained infectious. Failure to control MDRTB will have significant risks to public health. Shorter regimens are preferred by patients and are cheaper . Preliminary

2016 British Thoracic Society

177. Public health guidance on tuberculosis control in vulnerable and hard-to-reach populations

Public health guidance on tuberculosis control in vulnerable and hard-to-reach populations SCIENTIFIC ADVICE www.ecdc.europa.eu Guidance on tuberculosis control in vulnerable and hard-to-reach populations ECDC SCIENTIFIC ADVICE Guidance on tuberculosis control in vulnerable and hard-to-reach populations ii This guidance was coordinated by the ECDC project manager Andreas Sandgren, and produced by an ECDC editorial team consisting of Andreas Sandgren, Marieke J. van der Werf, Netta Beer (...) and the ad hoc scientific panel. In the process of developing this guidance document, four systematic reviews on interventions for tuberculosis identification and management in hard-to-reach and vulnerable populations were performed under service contract No. ECD.5078 (OJ/02/05/2014-PROC/2014/014), by the Academic Medical Centre, University of Amsterdam. We would like to acknowledge the work performed under the contract by Charlotte C. Heuvelings, Sophia G. de Vries, Patrick F. Greve, Benjamin J. Visser

2016 European Centre for Disease Prevention and Control - Public Health Guidance

178. Treatment of Drug-Susceptible Tuberculosis: Official ATS/CDC/IDSA Clinical Practice Guidelines

Treatment of Drug-Susceptible Tuberculosis: Official ATS/CDC/IDSA Clinical Practice Guidelines Clinical Infectious Diseases IDSA GUIDELINE Of?cial American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis Payam Nahid, 1 Susan E. Dorman, 2 Narges Alipanah, 1 Pennan M. Barry, 3 Jan L. Brozek, 4 Adithya Cattamanchi, 1 Lelia H. Chaisson, 1 Richard E. Chaisson, 2 Charles L (...) of Public Health, Richmond; 4 McMaster University, Hamilton, Ontario, Canada; 5 National Jewish Health, Denver, Colorado; 6 World Health Organization, Geneva, Switzerland; 7 Tuberculosis Control Section, San Francisco Department of Public Health, California; 8 Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia; 9 Harvard Medical School, Boston, Massachusetts; 10 McGill University

2016 American Thoracic Society

179. Diagnosis of Tuberculosis in Adults and Children

Diagnosis of Tuberculosis in Adults and Children Practice Guidelines Search Search Practice Guidelines Practice guidelines are systematically developed statements to assist practitioners and patients in making decisions about appropriate health care for specific clinical circumstances. Attributes of good guidelines include validity, reliability, reproducibility, clinical applicability, clinical flexibility, clarity, multidisciplinary process, review of evidence, and documentation. [Institute

2016 Infectious Diseases Society of America

180. Treatment of Drug-Susceptible Tuberculosis

Treatment of Drug-Susceptible Tuberculosis Practice Guidelines Search Search Practice Guidelines Practice guidelines are systematically developed statements to assist practitioners and patients in making decisions about appropriate health care for specific clinical circumstances. Attributes of good guidelines include validity, reliability, reproducibility, clinical applicability, clinical flexibility, clarity, multidisciplinary process, review of evidence, and documentation. [Institute

2016 Infectious Diseases Society of America